Enlivex Therapeutics Ltd (ENLV) - Total Liabilities

Latest as of September 2025: ILA3.46 Million ILA ≈ $9.27K USD

Based on the latest financial reports, Enlivex Therapeutics Ltd (ENLV) has total liabilities worth ILA3.46 Million ILA (≈ $9.27K USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Enlivex Therapeutics Ltd annual equity growth to track the company's year-over-year net asset growth rate.

Enlivex Therapeutics Ltd - Total Liabilities Trend (2012–2024)

This chart illustrates how Enlivex Therapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data. See ENLV FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Enlivex Therapeutics Ltd Competitors by Total Liabilities

The table below lists competitors of Enlivex Therapeutics Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Lavoro Limited Class A Ordinary Shares NASDAQ:LVRO	USA	$7.97 Billion
Baillie Gifford UK Growth Fund PLC LSE:BGUK	UK	GBX25.98 Million
DSJ Keep Learning Limited NSE:KEEPLEARN	India	Rs44.75 Million
TRU PRECIOUS METALS CORP. F:706	Germany	€301.38K
Argeo AS OL:ARGEO	Norway	Nkr57.18 Million
Oakajee Corporation Ltd AU:OKJ	Australia	AU$172.28K
Oculus VisionTech Inc V:OVT	Canada	CA$829.23K
Saferoads Holdings Ltd AU:SRH	Australia	AU$4.05 Million

Liability Composition Analysis (2012–2024)

This chart breaks down Enlivex Therapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Enlivex Therapeutics Ltd (ENLV) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	6.43	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.20	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.17	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Enlivex Therapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Enlivex Therapeutics Ltd (2012–2024)

The table below shows the annual total liabilities of Enlivex Therapeutics Ltd from 2012 to 2024.

Year	Total Liabilities	Change
2024-12-31	ILA4.10 Million ≈ $10.99K	-39.26%
2023-12-31	ILA6.75 Million ≈ $18.09K	-37.53%
2022-12-31	ILA10.80 Million ≈ $28.96K	+6.87%
2021-12-31	ILA10.11 Million ≈ $27.10K	+107.49%
2020-12-31	ILA4.87 Million ≈ $13.06K	-22.41%
2019-12-31	ILA6.28 Million ≈ $16.83K	+372.74%
2018-12-31	ILA1.33 Million ≈ $3.56K	+188.70%
2017-12-31	ILA460.00K ≈ $1.23K	-76.18%
2016-12-31	ILA1.93 Million ≈ $5.18K	-25.27%
2015-12-31	ILA2.58 Million ≈ $6.93K	+13.33%
2014-12-31	ILA2.28 Million ≈ $6.11K	+1640.46%
2013-12-31	ILA131.00K ≈ $351.21	+61.73%
2012-12-31	ILA81.00K ≈ $217.16	--

About Enlivex Therapeutics Ltd

TA:ENLV Israel Biotechnology

Market Cap

$2.98 Million

ILA1.11 Billion ILA

Market Cap Rank

#29495 Global

#432 in Israel

Share Price

ILA4.68

Change (1 day)

-31.78%

52-Week Range

ILA0.57 - ILA614.90

All Time High

ILA14150.00